Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06543537 · ClinicalTrials.gov registry record · NA

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

A NA study of Ovarian Cancer and Ovarian Neoplasms, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
112
Enrollment target
1
Study location

NCT06543537 is a NA study of Ovarian Cancer and Ovarian Neoplasms that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 112 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06543537, a NA study of Ovarian Cancer and Ovarian Neoplasms, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
112 participants
Enrollment target
1
Study location

Study Summary

This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)

Interventions

  • BEHAVIORAL Collaborative Agenda-Setting Intervention

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2025-01-17
Est. Completion 2026-12-31
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT06543537

The ClinicalTrials.gov registry entry for NCT06543537 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Collaborative Agenda-Setting Intervention is the first listed.

NCT06543537 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06543537 about?

NCT06543537 is a clinical study titled "Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer". This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)

What is the current status of trial NCT06543537?

This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2025-01-17. Estimated completion is 2026-12-31.

What conditions does trial NCT06543537 study?

This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma.

What interventions are being tested in trial NCT06543537?

The interventions under investigation include: Collaborative Agenda-Setting Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT06543537?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06543537 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.